Please use this identifier to cite or link to this item:
|Title:||The Basophil Surface Marker CD203c Identifies Aspergillus Sensitization in 2 Cystic Fibrosis||Authors:||Mirković, Bojana
Lavelle, Gillian M.
Azim, Ahmed Abdul
Gargoum, Fatma S.
Moss, Richard B.
Greene, Catherine M.
Chotirmall, Sanjay Haresh
McElvaney, Noel G.
|Keywords:||Basophil activation test
Body mass index
Allergic bronchopulmonary aspergillosis
|Issue Date:||2015||Source:||Mirković, B., Lavelle, G. M., Azim, A. A., Helma, K., Gargoum, F. S., Molloy, K., et al. (2015). The Basophil Surface Marker CD203c Identifies Aspergillus Sensitization in 2 Cystic Fibrosis. Journal of Allergy and Clinical Immunology, 137(2), 436-443.||Series/Report no.:||Journal of Allergy and Clinical Immunology||Abstract:||Background: Colonization by Aspergillus fumigatus in patients with cystic fibrosis (CF) can cause A fumigatus sensitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surface-expressed basophil marker CD203c in sensitized subjects, a response that can be readily measured by using flow cytometry. Objective: We sought to identify A fumigatus sensitization in patients with CF by using the basophil activation test (BAT). Methods: Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify A fumigatus sensitization. Serologic (total and A fumigatus–specific IgE), pulmonary function, and body mass index measurements were performed. Results: The BAT discriminates A fumigatus–sensitized from nonsensitized patients with CF. Persistent isolation of A fumigatus in sputum is a significant risk factor for A fumigatus sensitization. Levels of the A fumigatus–stimulated basophil activation marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus–sensitized but not nonsensitized patients with CF. Total and A fumigatus–specific IgE, but not IgG, levels are increased in A fumigatus–sensitized patients with CF and ABPA when compared with those in A fumigatus–sensitized and nonsensitized patients with CF without ABPA. Itraconazole treatment did not affect A fumigatus sensitization. Conclusion: Combining the BAT with routine serologic testing allows classification of patients with CF into 3 groups: nonsensitized, A fumigatus–sensitized, and ABPA. Accurate and prompt identification of A fumigatus–associated clinical status might allow early and targeted therapeutic intervention, potentially improving clinical outcomes.||URI:||https://hdl.handle.net/10356/81769
|ISSN:||0091-6749||DOI:||10.1016/j.jaci.2015.07.045||Rights:||© 2015 American Academy of Allergy, Asthma & Immunology. This is the author created version of a work that has been peer reviewed and accepted for publication in Journal of Allergy and Clinical Immunology, published by Elsevier Inc on behalf of American Academy of Allergy, Asthma & Immunology. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1016/j.jaci.2015.07.045].||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||LKCMedicine Journal Articles|
Files in This Item:
|Basophil Surface Marker CD203c identifies Aspergillus sensitization in cystic fibrosis.pdf||Main article||435.48 kB||Adobe PDF|
Updated on Jan 16, 2023
Web of ScienceTM
Updated on Feb 1, 2023
Page view(s) 50546
Updated on Jan 31, 2023
Updated on Jan 31, 2023
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.